These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32510723)

  • 1. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
    Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
    Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
    Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
    Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
    Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
    Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
    Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
    Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
    Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
    Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
    Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
    Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
    Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
    Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
    Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
    Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients.
    Cheng L; You X; Wang X; Yu M; Jia C
    Drug Des Devel Ther; 2024; 18():3617-3628. PubMed ID: 39156484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics.
    Chiang YH; Cheng CN; Chuang PJ; Chen YC; Chen YJ; Kuo CH; Lin SW; Chang LC
    Int J Antimicrob Agents; 2024 Jan; 63(1):107028. PubMed ID: 37931850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors Influencing and Adverse Reactions of Voriconazole Clearance in Patients with Hematological Diseases].
    Huang HG; Wang HL; Lin YK; Yi YD; Liu M; Dong JL; Liu JM; Chen F; Deng TY; Hu S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):562-567. PubMed ID: 37096534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.